Similarly, sirolimus, an mTOR inhibitor, has demonstrated activity in ccRCC due to the frequent dysregulation of the PI3K/AKT/mTOR pathway (9). This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.